ScreenerHero

PRGOPerrigo Company plc

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · perrigo.com
14.25USDMkt Cap: 1.98B $P/E: —

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap1.98B $
Enterprise Value5.05B $
Revenue (TTM)4.14B $
Gross Profit1.49B $
Net Income (TTM)-1.43B $
Revenue/Share29.83 USD
Last Price14.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8.1K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINIE00BGH1M568
Valuation
P/E (Trailing)—
P/E (Forward)5.94
PEG1.14
EV/EBITDA8.21
EV/Revenue1.22
P/S0.48
P/B0.79
EPS (TTM)-12.29
EPS (Forward)2.40
52W Range
13.5299% of range14.26
52W High14.26 USD
52W Low13.52 USD
Profitability
Gross Margin35.14%
Oper. Margin3.84%
EBITDA Margin14.85%
Profit Margin-33.51%
ROE-48.56%
ROA-16.70%
Growth
Revenue Growth-3.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF238.50M $
CapEx (TTM)93.40M $
FCF Margin10.55%
FCF Yield22.11%
Net Debt3.08B $
Net Debt/EBITDA5.00
Balance Sheet
Debt/Equity1.24
Current Ratio2.32
Quick Ratio1.09
Book Value/Sh18.14 USD
Cash/Share2.880 USD
Dividends
Fwd Div Rate1.160 USD
Trail. Div Rate1.160 USD
Div. Yield8.14%
5Y Avg Yield4.04%
Payout Ratio10950.00%
Ex-Div DateAug 28, 2026
Pay DateSep 15, 2026
Splits
Last Split2:1
Split DateAug 26, 1993
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.50 USD
Upside (mean)+15.8%
Target Range14.00 USD – 20.00 USD
$14.00+15.8% to mean$20.00
# Analysts4
Ownership
Shares Out.138.77M
Float138.08M
Insiders0.40%
Institutions120.64%
Short Interest
Short Ratio7.6d
Short % Float25.58%
Short % Out.16.68%
Shares Short23.15M
Short (prev mo.)24.58M
Technical
SMA 5011.09 (+28.5%)
SMA 20012.22 (+16.7%)
Beta0.54
S&P 52W Chg19.18%
Avg Vol (30d)2.58M
Avg Vol (10d)2.31M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—